L-carnitine forms compared: ALCAR vs L-tartrate vs L-carnitine
The three common forms are studied for different things: acetyl-L-carnitine (ALCAR) mainly in nerve and brain-related research, L-carnitine L-tartrate mainly in exercise recovery, and plain L-carnitine in deficiency and metabolic research. None has an established upper limit, but around 3 g a day can cause nausea, diarrhoea and a fishy body odour. Notably, a large randomised trial found ALCAR 3 g a day worsened, rather than prevented, chemotherapy-related nerve damage.
This article answers one question. For what L-Carnitine is, where it comes from and its other uses, see the L-Carnitine ingredient guide.
Key findings
- Forms are not interchangeable; research questions differ by form.
- About 3 g/day of carnitine can cause digestive effects and fishy body odour.
- ALCAR 3,000 mg/day increased taxane-induced neuropathy in a 409-person randomised trial.
- Carnitine can be converted by gut bacteria to TMAO, a compound under study for cardiovascular risk.
How the forms differ
| Form | What it is | Main research context | Key caution |
|---|---|---|---|
| Acetyl-L-carnitine (ALCAR) | L-carnitine bound to an acetyl group | Neuropathy and brain-related studies | Worsened chemotherapy-induced neuropathy in SWOG S0715 |
| L-carnitine L-tartrate (LCLT) | L-carnitine bound to tartaric acid | Exercise performance and recovery studies | Small, heterogeneous exercise trials |
| L-carnitine (base) | The carnitine molecule itself | Carnitine deficiency and metabolic studies | Digestive effects and odour at ~3 g/day |
Label amounts may refer to the whole compound (for example, ALCAR or LCLT) rather than the carnitine it provides, so the same milligram figure can deliver different amounts of carnitine.
Key human findings
ALCAR and chemotherapy: in a randomised, double-blind trial of 409 women receiving taxane chemotherapy for breast cancer, ALCAR 3,000 mg a day for 24 weeks did not prevent neuropathy and was associated with worse neuropathy at 24 weeks (Hershman et al., J Clin Oncol 2013 (SWOG S0715)); a follow-up found worse neuropathy persisted beyond treatment (JNCI 2018). LCLT and exercise: a systematic review examined L-carnitine forms, including LCLT, across exercise intensities, with small and varied trials (systematic review, 2021).
Evidence table
| Study or source | Population | What was tested | Main result | Limitations |
|---|---|---|---|---|
| Hershman et al., J Clin Oncol 2013 (SWOG S0715) | 409 women on taxane chemotherapy | ALCAR 3,000 mg/day vs placebo, 24 weeks | No prevention; worse neuropathy at 24 weeks | Specific population |
| Hershman et al., JNCI 2018 | Same trial, 2-year follow-up | — | Worse neuropathy with ALCAR persisted after treatment | Follow-up analysis |
| NIH ODS carnitine fact sheet | Safety overview | Carnitine supplements | ~3 g/day: GI effects and fishy odour; TMAO concerns; interactions | Summary |
Doses: what each number means
| Amount | What kind of figure it is | Context |
|---|---|---|
| ~3 g/day carnitine | Study dose | Amount at which digestive effects and odour are reported; also the ALCAR dose in SWOG S0715 |
| No tolerable upper limit | Regulatory | ODS: carnitine has no established UL |
| 500 mg–1 g capsules | Commercial dose | Common label amounts; check which form |
A dose used in a study describes what researchers gave participants. It is not a personal recommendation, and it does not mean a lower or higher amount is safe or effective for you.
Safety
- Around 3 g/day can cause nausea, vomiting, abdominal cramps, diarrhoea and a fishy body odour (NIH ODS carnitine fact sheet).
- Can cause muscle weakness in people with uraemia and seizures in people with seizure disorders (ODS).
- Gut bacteria can convert carnitine to TMAO, a compound associated with cardiovascular risk in observational research; implications are not well understood (ODS).
- People receiving chemotherapy should not use ALCAR to prevent neuropathy unless their oncology team advises it.
Interactions
The NIH ODS carnitine fact sheet notes that several medicine types can interact with carnitine and that people taking regular medicines should discuss carnitine use with a healthcare provider.
Limitations
- Few head-to-head comparisons of forms.
- Exercise trials are small and use varied protocols.
- Neuropathy findings depend on the population; the chemotherapy result may not apply to diabetic neuropathy.
Label checks
- Which form is used, and whether the amount refers to the compound or elemental carnitine.
- Total daily carnitine across products.
- Whether ALCAR is included in a neuropathy blend if you are having chemotherapy.
Related: acetyl-L-carnitine guide · L-carnitine L-tartrate guide · nerve support comparison
Frequently asked questions
What is the difference between ALCAR and L-carnitine?
ALCAR is L-carnitine with an acetyl group and is mainly studied in nerve and brain contexts; plain L-carnitine is studied mainly in deficiency and metabolism.
What is L-carnitine L-tartrate used for?
Mainly exercise performance and recovery research.
Is ALCAR good for chemotherapy neuropathy?
A large randomised trial found ALCAR 3 g a day made taxane-related neuropathy worse.
What are carnitine side effects?
Around 3 g a day can cause nausea, diarrhoea, cramps and a fishy body odour.
Is there an upper limit for carnitine?
No tolerable upper intake level has been established.
References
- Hershman et al., J Clin Oncol 2013 (SWOG S0715). Randomized double-blind placebo-controlled trial of acetyl-L-carnitine for the prevention of taxane-induced neuropathy. J Clin Oncol. 2013;31(20):2627–2633.
- Hershman DL, et al. Two-year trends of taxane-induced neuropathy in women enrolled in a randomized trial of acetyl-L-carnitine (SWOG S0715). JNCI. 2018;110(6):669–676.
- NIH ODS carnitine fact sheet.
- Effect of acute and chronic oral L-carnitine supplementation on exercise performance: a systematic review. 2021. PMC8704793